Agilon Health (NYSE:AGL) and Q Biomed (OTCMKTS:QBIO) Head to Head Contrast

Agilon Health (NYSE:AGL) and Q Biomed (OTCMKTS:QBIO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Agilon Health and Q Biomed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilon Health	2	8	5	0	2.20
Q Biomed	0	0	0	0	0.00

Agilon Health currently has a consensus target price of $58.73, indicating a potential downside of 48.06%. Given Q Biomed’s higher possible upside, analysts plainly believe Q Biomed is more favorable than Agilon Health.

Earnings and Valuation

This table compares Agilon Health and Q Biomed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilon Health	$5.93 billion	0.32	-$391.35 million	($21.56)	-5.24
Q Biomed	N/A	N/A	N/A	($0.02)	N/A

Q Biomed has lower revenue, but higher earnings than Agilon Health. Agilon Health is trading at a lower price-to-earnings ratio than Q Biomed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Agilon Health and Q Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agilon Health	-6.09%	-146.03%	-24.55%
Q Biomed	N/A	N/A	N/A

Summary

Q Biomed beats Agilon Health on 5 of the 8 factors compared between the two stocks.

About Agilon Health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.